Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 12/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | LIPE | Q05469 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9891849 | 0.90 | CNR2 (0.46) | CNR2CYP2D6KCNH2HRH3LIPE | |
| SCHEMBL16252997 | 0.89 | CNR2 (0.47) | CNR2LIPEALDH1A1 | |
| SCHEMBL22541590 | 0.74 | ALDH1A1 (0.44) | CNR2CYP2D6KCNH2HRH3ALDH1A1 | |
| SCHEMBL16253016 | 0.72 | ALDH1A1 (0.43) | CNR2CYP2D6KCNH2HRH3LIPE | |
| SCHEMBL9102235 | 0.72 | CNR2 (0.40) | CNR2RAB9A | |
| SCHEMBL16480409 | 0.71 | CNR2 (0.44) | CNR2LIPEALDH1A1 | |
| SCHEMBL27607371 | 0.71 | ALDH1A1 (0.46) | CNR2LIPEALDH1A1RAB9A | |
| SCHEMBL20702359 | 0.70 | RIPK1 (0.37) | CYP2D6KCNH2HRH3 | |
| SCHEMBL16254904 | 0.70 | HPGD (0.46) | CNR2LIPEALDH1A1 | |
| SCHEMBL16252989 | 0.70 | CNR2 (0.42) | CNR2CYP2D6KCNH2HRH3LIPE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8383615-B2 | Azetidine 2-carboxamide derivatives which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-02-26 | — | — | US | disclosed |
| US-20120142666-A1 | Azetidine 2-Carboxamide Derivatives Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142666-A1 | Azetidine 2-Carboxamide Derivatives Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | CNR2 1/4885CYP2D6 582/4885KCNH2 825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.